Paclitaxel + Carboplatin With/Out Cediranib Maleate in Stage III or Stage IV Non-Small Cell Lung Cancer

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

November 3, 2005

Primary Completion Date

July 4, 2008

Study Completion Date

January 10, 2013

Conditions
Lung Cancer
Interventions
DRUG

carboplatin

Given IV

DRUG

cediranib maleate

Given orally

DRUG

paclitaxel

Given IV

OTHER

placebo

Given orally

Trial Locations (20)

1426

Instituto Alexander Fleming, Buenos Aires

1437

Compleso Medico de la Policia Federal Argentina, Buenos Aires

2400

Clinical County Hospital of Sibiu, Sibiu

3004

Alfred Hospital, Melbourne

3400

"Oncological Institute Ion Chiricuta", Cluj-Napoca

119074

National University Hospital, Singapore

B1629AHJ

Hospital Universitario Austral, Buenos Aires

CEP20231-050

Instituto Nacional de Cancer (INCA), Rio de Janeiro

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BCCA - Vancouver Cancer Centre, Vancouver

P3E 5J1

Northeast Cancer Center Health Sciences, Greater Sudbury

L8V 5C2

Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton

N6A 4L6

London Regional Cancer Program, London

K1H 8L6

Ottawa Health Research Institute - General Division, Ottawa

P6B 0A8

Algoma District Cancer Program, Sault Ste. Marie

L2R 7C6

Niagara Health System, St. Catharines

M5G 1X5

Mount Sinai Hospital, Toronto

M5G 2M9

Univ. Health Network-Princess Margaret Hospital, Toronto

G1V 4G5

University Institute of Cardiology and, Québec

Unknown

Oncology Institute Bucharest, Bucharest

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK